Clinical Trial

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

Name: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. — clinical trial record (NCT07244380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.

Trial Details

NCT Number	NCT07244380
Lead Sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Conditions	T Lymphoblastic Leukemia/Lymphoma
Enrollment	38 participants
Start Date	2025-11-28
Primary Completion	2026-09-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-24